Salmon S E
Prog Clin Biol Res. 1980;48:291-312.
The potential applications of the human tumor stem cell assay to primary drug screening and Phase I-II new drug evaluation are of very broad scope and have not been completely addressed in this exploratory analysis. As in most other areas of science, careful and stepwise testing in many laboratories will be required to confirm or refute the utility of these approaches. Of the two areas discussed, the applications to new drug screening are still most uncertain and subject to change. From my perspective, in vitro growth conditions, for clonogenic human tumor cells, are perhaps at a similar stage of development as culture techniques for bacterial cells were in the 1930s. Availability of those techniques, and a combination of good ideas, serendipidy, and hard work led to the subsequent development of penicillin and other antibiotics which now can be used to cure most forms of infectious disease. The value of a simple and reproducible assay for screening therefore cannot be overemphasized. Applications of the tumor stem cell assay to Phase I-II drug evaluation already show preliminary signs of utility. Given this background and the more limited preclinical data on other agents now under study, broadened testing of this approach to new drug screening appears warranted. If use of an in vitro approach such as this proves successful for both primary and secondary screening, it would not be surprising if significant qualitative and quantitative changes occurred in the areas of new drug development and cancer clinical trials.
人肿瘤干细胞检测在初级药物筛选和I-II期新药评估中的潜在应用范围非常广泛,在本探索性分析中尚未得到全面探讨。与大多数其他科学领域一样,需要许多实验室进行仔细的逐步测试,以证实或反驳这些方法的实用性。在讨论的两个领域中,应用于新药筛选的情况仍然最不确定且可能会发生变化。在我看来,对于具有克隆形成能力的人肿瘤细胞,体外生长条件可能正处于与20世纪30年代细菌细胞培养技术相似的发展阶段。这些技术的可用性,再加上好的想法、意外发现和努力工作,促成了青霉素和其他抗生素的后续研发,现在这些抗生素可用于治疗大多数形式的传染病。因此,一种简单且可重复的筛选检测方法的价值再怎么强调也不为过。肿瘤干细胞检测在I-II期药物评估中的应用已显示出初步的实用迹象。鉴于此背景以及目前正在研究的其他药物的临床前数据较为有限,扩大这种新药筛选方法的测试似乎是有必要的。如果像这样的体外方法在初级和二级筛选中都证明是成功的,那么新药开发和癌症临床试验领域发生重大的定性和定量变化也就不足为奇了。